EP3612191B1 - Verfahren und zusammensetzungen zur behandlung von skelettmuskeldystrophie - Google Patents

Verfahren und zusammensetzungen zur behandlung von skelettmuskeldystrophie

Info

Publication number
EP3612191B1
EP3612191B1 EP18788380.6A EP18788380A EP3612191B1 EP 3612191 B1 EP3612191 B1 EP 3612191B1 EP 18788380 A EP18788380 A EP 18788380A EP 3612191 B1 EP3612191 B1 EP 3612191B1
Authority
EP
European Patent Office
Prior art keywords
cdcs
cdc
subject
mdx
xos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP18788380.6A
Other languages
English (en)
French (fr)
Other versions
EP3612191A4 (de
EP3612191A1 (de
Inventor
Eduardo MARBÁN
Mark A. Aminzadeh
Russell Rogers
Jennifer MOSELEY
Luis RODRIGUEZ-BORLADO
Saravana KANAGAVELU
Christopher Stewart Sakoda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Capricor Inc
Original Assignee
Cedars Sinai Medical Center
Capricor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center, Capricor Inc filed Critical Cedars Sinai Medical Center
Priority to EP25210912.9A priority Critical patent/EP4699658A2/de
Publication of EP3612191A1 publication Critical patent/EP3612191A1/de
Publication of EP3612191A4 publication Critical patent/EP3612191A4/de
Application granted granted Critical
Publication of EP3612191B1 publication Critical patent/EP3612191B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)

Claims (13)

  1. Kardiosphären-abgeleitete Zellen (CDCs) für die Verwendung bei der Behandlung von Skelettmuskeldystrophie bei einem Subjekt, wobei die Behandlung eine Verabreichung einer therapeutisch wirksamen Menge von CDCs, die zur Behandlung eines dystrophischen Skelettmuskels des Subjekts ausreicht, umfasst, wobei das Subjekt ein Mensch ist, wobei die Verabreichung intravenöse Injektion umfasst.
  2. CDCs für die Verwendung nach Anspruch 1, wobei die Verabreichung einer therapeutisch wirksamen Menge von CDCs über zwei oder mehr Verabreichungen erfolgt.
  3. CDCs für die Verwendung nach Anspruch 2, wobei die zwei oder mehr Verabreichungen von CDCs in Abständen von drei Monaten gegeben werden, um eine therapeutisch wirksame Menge von CDCs an einen Zielskelettmuskel abzugeben.
  4. CDCs für die Verwendung nach einem der Ansprüche 1-3, wobei die therapeutisch wirksame Menge von CDCs 150 x 106 CDCs beträgt oder mindestens beträgt.
  5. Zusammensetzung, die eine therapeutisch wirksame Menge von Kardiosphärenabgeleiteten Zellen (CDCs) umfasst, für die Verwendung in einem Verfahren zur Behandlung von Skelettmuskeldystrophie bei einem Subjekt, das diese benötigt, wobei die Behandlung Folgendes umfasst:
    Verabreichen einer ersten Dosis der Zusammensetzung an das Subjekt,
    wobei die therapeutisch wirksame Menge der ersten Dosis im Bereich von 1 x 107 bis 1 x 109 CDCs liegt;
    Abwarten einer ersten Zeitdauer nach Verabreichung der ersten Dosis,
    wobei die erste Zeitdauer zwischen 1 und 6 Monaten beträgt;
    Verabreichen einer zweiten Dosis einer Zusammensetzung, die eine therapeutisch wirksame Menge von CDCs umfasst, an das Subjekt,
    wobei die therapeutisch wirksame Menge der zweiten Dosis im Bereich von 1 x 107 bis 1 x 109 CDCs liegt;
    Abwarten einer zweiten Zeitdauer nach Verabreichung der zweiten Dosis,
    wobei die zweite Zeitdauer zwischen 1 und 6 Monaten beträgt;
    Verabreichen von mindestens einer zusätzlichen Dosis einer Zusammensetzung, die eine therapeutisch wirksame Menge von CDCs umfasst, an das Subjekt,
    wobei die therapeutisch wirksame Menge der mindestens einen zusätzlichen Dosis im Bereich von 1 x 107 bis 1 x 109 CDCs liegt; und
    Abwarten von mindestens einer zusätzlichen Zeitdauer nach Verabreichung der mindestens einen zusätzlichen Dosis,
    wobei die zweite Zeitdauer zwischen 1 und 6 Monaten beträgt;
    wobei die Verabreichungen zu einer Verbesserung von körperlicher Belastbarkeit oder Muskelfunktion führen,
    wobei die CDCs in Bezug auf das Subjekt allogen sind,
    wobei die Verabreichungen keine signifikante Immunantwort bei dem Subjekt induzieren,
    wobei die Verabreichungen systemische Verabreichung umfassen,
    wobei das Subjekt ein Mensch ist und
    wobei die Verabreichung intravenöse Injektion umfasst.
  6. CDCs für die Verwendung nach einem der Ansprüche 1-4 oder die Zusammensetzung für die Verwendung nach Anspruch 5, wobei eine Verabreichung die Expression von einem oder mehreren Markern von T-Zell-Aktivierung oder -Proliferation verändert.
  7. CDCs für die Verwendung nach einem der Ansprüche 1-4 oder Anspruch 6 oder die Zusammensetzung für die Verwendung nach einem der Ansprüche 5 oder 6, wobei einer oder mehrere Marker von T-Zell-Aktivierung oder -Proliferation CD69 und HLA-DR umfassen.
  8. CDCs für die Verwendung nach einem der Ansprüche 1-4 oder Anspruch 6 oder 7, wobei die Verwendung Folgendes umfasst:
    Verabreichen von mindestens zwei Dosen einer therapeutisch wirksamen Menge von CDCs an das Subjekt;
    wobei die mindestens zwei Dosen 1 bis 6 Monate getrennt voneinander verabreicht werden; und
    wobei das Verabreichen von mindestens zwei Dosen einer therapeutisch wirksamen Menge von CDCs an das Subjekt keine signifikante Immunantwort bei dem Subjekt induziert.
  9. CDCs für die Verwendung nach einem der Ansprüche 1-4 oder Anspruch 6-8 oder die Zusammensetzung für die Verwendung nach einem der Ansprüche 5-7, wobei die Skelettmuskeldystrophie die Duchenne-Muskeldystrophie (DMD) umfasst, die einen dystrophischen Skelettmuskel involviert.
  10. CDCs für die Verwendung nach einem der Ansprüche 1-4 oder Anspruch 6-9 oder die Zusammensetzung für die Verwendung nach einem der Ansprüche 5-7 oder 9, wobei der dystrophische Skelettmuskel einen dystrophischen Skelettmuskel des Diaphragmas, des Arms oder des Beins umfasst.
  11. CDCs für die Verwendung nach einem der Ansprüche 1-4 oder Anspruch 6-10 oder die Zusammensetzung für die Verwendung nach einem der Ansprüche 5-7, 9 oder 10, wobei die mindestens zwei Dosen oder die erste und zweite Dosis 6 Wochen getrennt voneinander verabreicht werden.
  12. CDCs für die Verwendung nach einem der Ansprüche 1, 2 oder 4, wobei die therapeutisch wirksame Menge von CDCs 1 x 107 bis 1 x 109 CDCs umfasst.
  13. CDCs für die Verwendung nach einem der Ansprüche 1-4, 6-10 oder 12 oder die Zusammensetzung für die Verwendung nach einem der Ansprüche 5-7, 9 oder 10, wobei die CDCs allogene menschliche CDCs sind.
EP18788380.6A 2017-04-19 2018-04-18 Verfahren und zusammensetzungen zur behandlung von skelettmuskeldystrophie Active EP3612191B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP25210912.9A EP4699658A2 (de) 2017-04-19 2018-04-18 Verfahren und zusammensetzungen zur behandlung von skelettmuskeldystrophie

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762487393P 2017-04-19 2017-04-19
US201762487402P 2017-04-19 2017-04-19
US201762487408P 2017-04-19 2017-04-19
US201762535672P 2017-07-21 2017-07-21
US201762569440P 2017-10-06 2017-10-06
US201862614753P 2018-01-08 2018-01-08
PCT/US2018/028184 WO2018195210A1 (en) 2017-04-19 2018-04-18 Methods and compositions for treating skeletal muscular dystrophy

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP25210912.9A Division-Into EP4699658A2 (de) 2017-04-19 2018-04-18 Verfahren und zusammensetzungen zur behandlung von skelettmuskeldystrophie
EP25210912.9A Division EP4699658A2 (de) 2017-04-19 2018-04-18 Verfahren und zusammensetzungen zur behandlung von skelettmuskeldystrophie

Publications (3)

Publication Number Publication Date
EP3612191A1 EP3612191A1 (de) 2020-02-26
EP3612191A4 EP3612191A4 (de) 2020-12-30
EP3612191B1 true EP3612191B1 (de) 2026-03-11

Family

ID=63856114

Family Applications (2)

Application Number Title Priority Date Filing Date
EP25210912.9A Pending EP4699658A2 (de) 2017-04-19 2018-04-18 Verfahren und zusammensetzungen zur behandlung von skelettmuskeldystrophie
EP18788380.6A Active EP3612191B1 (de) 2017-04-19 2018-04-18 Verfahren und zusammensetzungen zur behandlung von skelettmuskeldystrophie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP25210912.9A Pending EP4699658A2 (de) 2017-04-19 2018-04-18 Verfahren und zusammensetzungen zur behandlung von skelettmuskeldystrophie

Country Status (6)

Country Link
US (2) US11759482B2 (de)
EP (2) EP4699658A2 (de)
JP (3) JP7336769B2 (de)
AU (2) AU2018255346B2 (de)
CA (1) CA3059910A1 (de)
WO (1) WO2018195210A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
AU2013302799B2 (en) 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
EP3402543B1 (de) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Aus kardiosphäre stammende zellen und durch solche zellen sekretierte exosomen in der behandlung von herzversagen mit konservierter auswurffraktion
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
EP4699658A2 (de) * 2017-04-19 2026-02-25 Cedars-Sinai Medical Center Verfahren und zusammensetzungen zur behandlung von skelettmuskeldystrophie
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
US12146137B2 (en) 2018-02-05 2024-11-19 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and Y-RNAS
JP2022104813A (ja) * 2020-12-29 2022-07-11 アイ ピース，インコーポレイテッド リプログラミング因子を導入された細胞の培養方法
EP4230196A1 (de) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Verbindungen zur verwendung bei der behandlung von dystrophinopathien
WO2025085731A1 (en) * 2023-10-18 2025-04-24 Children's National Medical Center TRANSFORMING GROWTH FACTOR ß (TGF-ß) OLIGONUCLEOTIDE COMBINATION THERAPY FOR TREATING MUSCULOSKELETAL DISEASES
WO2025122177A1 (en) * 2023-12-05 2025-06-12 Leksum LLC Extracellular vesicles for therapy

Family Cites Families (365)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3470876A (en) 1966-09-28 1969-10-07 John Barchilon Dirigible catheter
US4106488A (en) 1974-08-20 1978-08-15 Robert Thomas Gordon Cancer treatment method
US3964468A (en) 1975-05-30 1976-06-22 The Board Of Trustees Of Leland Stanford Junior University Bioptome
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
GB8711614D0 (en) 1987-05-16 1987-06-24 Medical Res Council Proteins
US4960134A (en) 1988-11-18 1990-10-02 Webster Wilton W Jr Steerable catheter
US5175004A (en) 1988-12-27 1992-12-29 Matsumura Kenneth N Propagatable, new combinant cells for cellular replacement therapy
US4921482A (en) 1989-01-09 1990-05-01 Hammerslag Julius G Steerable angioplasty device
US5052402A (en) 1989-01-31 1991-10-01 C.R. Bard, Inc. Disposable biopsy forceps
US5104787A (en) 1990-03-05 1992-04-14 Lindstrom Richard L Method for apparatus for a defined serumfree medical solution useful for corneal preservation
US6326198B1 (en) 1990-06-14 2001-12-04 Regents Of The University Of Michigan Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
ES2077007T3 (es) 1990-12-07 1995-11-16 Ruesch Willy Ag Instrumento medico con cabeza orientable.
US5228441A (en) 1991-02-15 1993-07-20 Lundquist Ingemar H Torquable catheter and method
US5454787A (en) 1991-02-15 1995-10-03 Lundquist; Ingemar H. Torquable tubular assembly and torquable catheter utilizing the same
AU660444B2 (en) 1991-02-15 1995-06-29 Ingemar H. Lundquist Torquable catheter and method
US5329923A (en) 1991-02-15 1994-07-19 Lundquist Ingemar H Torquable catheter
US5315996A (en) 1991-02-15 1994-05-31 Lundquist Ingemar H Torquable catheter and method
US5981165A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
US5287857A (en) 1992-06-22 1994-02-22 David Mann Apparatus and method for obtaining an arterial biopsy
US5334145A (en) 1992-09-16 1994-08-02 Lundquist Ingemar H Torquable catheter
US5243167A (en) 1992-09-16 1993-09-07 Ingemar H. Lundquist Apparatus and method for manufacturing a slotted torque tube
US5383852A (en) 1992-12-04 1995-01-24 C. R. Bard, Inc. Catheter with independent proximal and distal control
US5368564A (en) 1992-12-23 1994-11-29 Angeion Corporation Steerable catheter
US5492825A (en) 1993-08-06 1996-02-20 The Regents Of The University Of California Mammalian inward rectifier potassium channel cDNA, IRK1, corresponding vectors, and transformed cells
US5616568A (en) 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
US5454827A (en) 1994-05-24 1995-10-03 Aust; Gilbert M. Surgical instrument
US5840502A (en) 1994-08-31 1998-11-24 Activated Cell Therapy, Inc. Methods for enriching specific cell-types by density gradient centrifugation
US5702905A (en) 1994-09-28 1997-12-30 Spectral Diagnostics Monoclonal antibody to human ventricular myosin light chains
DE69621528T2 (de) 1995-02-07 2003-01-16 Shiseido Co. Ltd., Tokio/Tokyo Anti-inflamatorische agenzien
US5551427A (en) 1995-02-13 1996-09-03 Altman; Peter A. Implantable device for the effective elimination of cardiac arrhythmogenic sites
US5715832A (en) 1995-02-28 1998-02-10 Boston Scientific Corporation Deflectable biopsy catheter
US5925567A (en) 1995-05-19 1999-07-20 T. Breeders, Inc. Selective expansion of target cell populations
US5702433A (en) 1995-06-27 1997-12-30 Arrow International Investment Corp. Kink-resistant steerable catheter assembly for microwave ablation
BR9610058A (pt) 1995-07-28 1999-07-27 Marie Curie Cancer Care Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
DE69635899T2 (de) 1995-11-17 2006-11-23 Asahi Kasei Kabushiki Kaisha Polypeptid, das die differenzierung unterdrueckt
US5762069A (en) 1995-12-29 1998-06-09 Akos Biomedical, Inc. Multiple sample biopsy forceps
US5856155A (en) 1996-02-23 1999-01-05 The Johns Hopkins University School Of Medicine Compounds and related methods for modulating potassium ion channels and assays for such compounds
US5824031A (en) 1996-02-28 1998-10-20 Cardio Source Apparatus and method for deflecting a tip of a lead or catheter
US6132390A (en) 1996-02-28 2000-10-17 Eupalamus Llc Handle for manipulation of a stylet used for deflecting a tip of a lead or catheter
US5782748A (en) 1996-07-10 1998-07-21 Symbiosis Corporation Endoscopic surgical instruments having detachable proximal and distal portions
GB9615726D0 (en) 1996-07-26 1996-09-04 Medical Res Council Anti-viral agent 11
US5955275A (en) 1997-02-14 1999-09-21 Arcaris, Inc. Methods for identifying nucleic acid sequences encoding agents that affect cellular phenotypes
US6017735A (en) 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US6443949B2 (en) 1997-03-13 2002-09-03 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6086582A (en) 1997-03-13 2000-07-11 Altman; Peter A. Cardiac drug delivery system
US6511477B2 (en) 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6416510B1 (en) 1997-03-13 2002-07-09 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
US6547787B1 (en) 1997-03-13 2003-04-15 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6099832A (en) 1997-05-28 2000-08-08 Genzyme Corporation Transplants for myocardial scars
US5899914A (en) 1997-06-11 1999-05-04 Endius Incorporated Surgical instrument
US5851212A (en) 1997-06-11 1998-12-22 Endius Incorporated Surgical instrument
US6004295A (en) 1997-06-26 1999-12-21 An-Go-Gen Inc. Catheters
CA2296704C (en) 1997-07-14 2010-10-19 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
US6123699A (en) 1997-09-05 2000-09-26 Cordis Webster, Inc. Omni-directional steerable catheter
US7037648B1 (en) 1997-11-07 2006-05-02 John Hopkins University Somatic transfer of modified genes to predict drug effects
US5938603A (en) 1997-12-01 1999-08-17 Cordis Webster, Inc. Steerable catheter with electromagnetic sensor
US6203487B1 (en) 1997-12-31 2001-03-20 Thomas Jefferson University Use of magnetic particles in the focal delivery of cells
WO1999039624A1 (en) 1998-02-05 1999-08-12 Biosense Inc. Intracardiac drug delivery
EP1064356A2 (de) 1998-03-23 2001-01-03 ZymoGenetics, Inc. Herz-derivierte stammzellen
US20010044619A1 (en) 1998-04-08 2001-11-22 Peter A. Altman Cardiac drug delivery system and method for use
US6296630B1 (en) 1998-04-08 2001-10-02 Biocardia, Inc. Device and method to slow or stop the heart temporarily
US6171610B1 (en) 1998-04-24 2001-01-09 University Of Massachusetts Guided development and support of hydrogel-cell compositions
US6540725B1 (en) 1998-06-04 2003-04-01 Biosense Webster, Inc. Injection catheter with controllably extendable injection needle
US6165164A (en) 1999-03-29 2000-12-26 Cordis Corporation Catheter for injecting therapeutic and diagnostic agents
DE19833476B4 (de) 1998-07-24 2005-08-25 Huss, Ralf, Dr. Genetisch modifizierte CD34-Negative, adhärent wachsende hämatopoetische Stammzellen und deren Verwendung in der Gentherapie
US6102887A (en) 1998-08-11 2000-08-15 Biocardia, Inc. Catheter drug delivery system and method for use
US6074408A (en) 1998-10-13 2000-06-13 Freeman; Kenneth V. Modular medical instrument and method of using same
US6153582A (en) 1998-11-05 2000-11-28 Bausch & Lomb Surgical, Inc. Defined serumfree medical solution for ophthalmology
US6572611B1 (en) 1998-11-23 2003-06-03 C. R. Bard, Inc. Intracardiac grasp catheter
US6193763B1 (en) 1998-12-17 2001-02-27 Robert A. Mackin Apparatus and method for contemporaneous treatment and fluoroscopic mapping of body tissue
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6783510B1 (en) 1999-07-08 2004-08-31 C.R. Bard, Inc. Steerable catheter
AU6519100A (en) 1999-08-05 2001-03-05 Biocardia, Inc. A system and method for delivering thermally sensitive and reverse-thermal gelation matrials
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
SE9903185D0 (sv) 1999-09-08 1999-09-08 Europ I Of Science Ab Terapeutisk metod och anordning baserad på magnetism
AU7378600A (en) * 1999-09-14 2001-04-17 Children's Medical Center Corporation Methods for treating muscular dystrophy
US20030161817A1 (en) 2001-03-28 2003-08-28 Young Henry E. Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
EP1218489B1 (de) 1999-09-24 2009-03-18 Cybios LLC Pluripotent embryonale stammzellen-ähnliche zellen, zusammensetzungen und ihre vervendungen
US6716242B1 (en) 1999-10-13 2004-04-06 Peter A. Altman Pulmonary vein stent and method for use
AU8023200A (en) 1999-10-13 2001-04-23 Biocardia, Inc. Pulmonary vein stent and method for use
US6224587B1 (en) 1999-11-22 2001-05-01 C.R. Bard, Inc. Steerable catheter
AU4305101A (en) 1999-11-22 2001-06-04 Research Foundation Of The State University Of New York, The Magnetic nanoparticles for selective therapy
US20010046489A1 (en) 1999-12-06 2001-11-29 Habener Joel E. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
EP1254952A4 (de) 1999-12-28 2004-09-22 Kyowa Hakko Kogyo Kk Zellen die in der lage sind in herzmuskelzellen zu differenzieren
AU2001234470A1 (en) 2000-01-14 2001-07-24 Beth Israel Deaconess Medical Center Cardiac-cell specific enhancer elements and uses thereof
US6530944B2 (en) 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US6585716B2 (en) 2000-04-05 2003-07-01 Biocardia, Inc. Method of treating the heart
US6478776B1 (en) 2000-04-05 2002-11-12 Biocardia, Inc. Implant delivery catheter system and methods for its use
US20040087016A1 (en) 2000-05-12 2004-05-06 University Of Utah Research Foundation Compositions and methods for cell dedifferentiation and tissue regeneration
WO2002005866A2 (en) 2000-07-13 2002-01-24 Bioheart, Inc. Deployment system for myocardial cellular material
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US20110091428A1 (en) 2000-07-31 2011-04-21 New York Medical College Compositions of adult organ stem cells and uses thereof
WO2002013760A2 (en) 2000-07-31 2002-02-21 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
AU2001284695A1 (en) 2000-07-31 2002-02-13 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
EP1324780A4 (de) 2000-09-06 2005-06-22 Univ Johns Hopkins Methoden zur behandlung von herzarrhythmie
US20040254134A1 (en) 2001-04-27 2004-12-16 Eduardo Marban Biological pacemaker
US6569105B1 (en) 2000-09-14 2003-05-27 Syntheon, Llc Rotatable and deflectable biopsy forceps
FR2814752A1 (fr) 2000-10-02 2002-04-05 Chru Lille Procede d'obtention in vitro de cellules insulino- secretrices de mammifere et leurs utilisations
US6511471B2 (en) 2000-12-22 2003-01-28 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
EP2316918B1 (de) 2001-02-14 2015-07-01 Anthrogenesis Corporation Post-Partum Säugetier-Plazenta, deren Verwendung und daraus gewonnene Stammzellen
EP1372916A2 (de) 2001-03-21 2004-01-02 Vitrox APS Verfahren und gehäuse zum bearbeiten von materialien
AU2002306865A1 (en) 2001-03-23 2003-03-03 Warren J. Alilain Generation of multipotent central nervous system stem cells
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
CA2351156A1 (en) 2001-07-04 2003-01-04 Peter W. Zandstra A bioprocess for the generation of pluripotent cell derived cells and tissues
US6796963B2 (en) 2001-07-10 2004-09-28 Myocardial Therapeutics, Inc. Flexible tissue injection catheters with controlled depth penetration
WO2003006950A2 (en) 2001-07-12 2003-01-23 Geron Corporation Cells of the cardiomyocyte lineage produced from human pluripotent stem cells
IL159895A0 (en) 2001-07-20 2004-06-20 Technion Res & Dev Foundation Methods of generating human cardiac cells and tissues and uses thereof
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7731648B2 (en) 2001-07-25 2010-06-08 Aduro Biotech Magnetic nanoscale particle compositions, and therapeutic methods related thereto
WO2003018780A1 (en) 2001-08-27 2003-03-06 Advanced Cell Technology, Inc. De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
US6805860B1 (en) 2001-09-30 2004-10-19 Eckhard Alt Method of transluminal application of myogenic cells for repair or replacement of heart tissue
US7452532B2 (en) 2001-09-30 2008-11-18 Scicotec Gmbh Transluminal application of adult stem cells for body organ tissue repair
US20030082153A1 (en) 2001-10-22 2003-05-01 The Government Of The United States Of America Stem cells that transform to beating cardiomyocytes
WO2003039382A2 (en) 2001-11-05 2003-05-15 Medgenics, Inc. System for processing tissue
DE10162353A1 (de) 2001-12-18 2003-07-03 Roehm Gmbh Extrusionsdüse für Folien oder Platten mit seitlicher Schmelzeeinspeisung
US20040014209A1 (en) 2002-01-23 2004-01-22 Lassar Andrew B. Compositions and methods for modulating cell differentiation
GB0202149D0 (en) 2002-01-30 2002-03-20 Univ Edinburgh Pluripotency determining factors and uses thereof
TWI288779B (en) 2002-03-28 2007-10-21 Blasticon Biotech Forschung Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
US6866117B2 (en) 2002-04-05 2005-03-15 Wing Enterprises, Inc. Light weight ladder systems and methods
US7840261B2 (en) 2002-06-05 2010-11-23 Biocardia, Inc. Catheter systems and methods for placing bi-ventricular pacing leads
AU2003299509A1 (en) 2002-06-21 2004-05-13 University Of Utah Research Foundation Crosslinked compounds and methods of making and using thereof
EP1545219A4 (de) 2002-07-23 2009-09-30 Boston Scient Ltd Zellentherapie zur regeneration
JP2005534345A (ja) 2002-07-29 2005-11-17 エス セル インターナショナル ピーティーイー リミテッド インスリン陽性、グルコース応答性細胞の分化のための多段階方法
AU2003270051A1 (en) 2002-08-29 2004-03-19 Baylor College Of Medicine Heart derived cells for cardiac repair
US20040258669A1 (en) 2002-11-05 2004-12-23 Dzau Victor J. Mesenchymal stem cells and methods of use thereof
US7794702B2 (en) 2003-01-15 2010-09-14 The Trustees Of Columbia University In The City Of New York Mesenchymal stem cells as a vehicle for ion channel transfer in syncytial structures
EP1590446A4 (de) 2003-01-31 2006-12-27 Univ California Verwendung von islet 1 als marker zur isolierung oder erzeugung von stammzellen
DE10331439B3 (de) 2003-07-10 2005-02-03 Micromod Partikeltechnologie Gmbh Magnetische Nanopartikel mit verbesserten Magneteigenschaften
SI1601770T1 (sl) 2003-03-04 2010-01-29 Intercell Ag Streptococcus pyogenes antigeni
US7837631B2 (en) 2003-03-14 2010-11-23 Boston Scientific Scimed Inc. Biopsy forceps with removable jaw segments
US20060041182A1 (en) 2003-04-16 2006-02-23 Forbes Zachary G Magnetically-controllable delivery system for therapeutic agents
US20040214182A1 (en) 2003-04-25 2004-10-28 Vinod Sharma Genetic modification of targeted regions of the cardiac conduction system
US7329638B2 (en) 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
US20060025713A1 (en) 2003-05-12 2006-02-02 Alex Rosengart Magnetic particle-based therapy
CA2431425A1 (en) 2003-06-05 2004-12-05 Angiogene, Inc. Epas1 gene transfer to improve cell therapy
GB0313259D0 (en) 2003-06-09 2003-07-16 Consejo Superior Investigacion Magnetic nanoparticles
ES2265199B1 (es) 2003-06-12 2008-02-01 Cellerix, S.L. Celulas madre adultas multipotentes procedentes de condrocitos desdiferenciados y sus aplicaciones.
JP2007500756A (ja) 2003-06-12 2007-01-18 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 組織または器官を標的化するための細胞の指向
EP2399990B1 (de) 2003-06-27 2015-07-22 DePuy Synthes Products, Inc. Zellen von post-partum Nabelschnur zur Verwendung bei der Behandlung von Herz-Kreislauferkrankungen
CN101173250B (zh) 2003-06-30 2011-01-26 卫材R&D管理有限公司 磁性细胞及其使用方法
US20060205071A1 (en) 2003-07-17 2006-09-14 Gamida-Cell Ltd. Methods for ex-vivo expanding stem/progenitor cells
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US20080213812A1 (en) 2003-09-29 2008-09-04 Andrews William H Methods and compositions for modulating telomerase reverse transcriptase (TERT) expression
JP2005110565A (ja) 2003-10-07 2005-04-28 Nobuya Yamanaka 分化多能性維持剤
US7280863B2 (en) 2003-10-20 2007-10-09 Magnetecs, Inc. System and method for radar-assisted catheter guidance and control
CN1537646A (zh) 2003-10-22 2004-10-20 高春平 肿瘤局部综合治疗方法和装置
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
US7951592B2 (en) 2003-11-10 2011-05-31 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
GB0329310D0 (en) 2003-12-18 2004-01-21 Univ Keele Method
US7625581B2 (en) 2003-12-19 2009-12-01 Ethicon, Inc. Tissue scaffolds for use in muscoloskeletal repairs
US20070196281A1 (en) 2003-12-31 2007-08-23 Sungho Jin Method and articles for remote magnetically induced treatment of cancer and other diseases, and method for operating such article
WO2005076743A2 (en) 2004-02-17 2005-08-25 Yeda Research And Development Co. Ltd. Disaccharide molecules and derivatives thereof and methods of using same
US7780873B2 (en) 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
US20050260748A1 (en) 2004-02-27 2005-11-24 Michigan State University Adult stem cells and uses thereof
US20050214938A1 (en) 2004-03-26 2005-09-29 Gold Joseph D Cardiac bodies: clusters of spontaneously contracting cells for regenerating cardiac function
WO2005095652A2 (en) 2004-03-31 2005-10-13 Georgetown University Pnmt as a novel marker for progenitor cells
US20070231393A1 (en) 2004-05-19 2007-10-04 University Of South Carolina System and Device for Magnetic Drug Targeting with Magnetic Drug Carrier Particles
WO2005113754A1 (en) 2004-05-20 2005-12-01 New York Medical College Pluripotent adult stem cells
JP2006006125A (ja) 2004-06-22 2006-01-12 Nipro Corp 骨髄単核細胞の調製方法及び細胞調製装置
US20060018897A1 (en) 2004-06-28 2006-01-26 Transtarget Inc. Bispecific antibodies
KR20070058441A (ko) 2004-07-01 2007-06-08 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 면역억제성 엑소솜
EP1765980A4 (de) 2004-07-02 2007-12-12 Cytori Therapeutics Inc Systeme und verfahren zur isolierung und verwendung klinisch sicherer, aus fettgewebe stammender regenerativer zellen
US20070196918A1 (en) 2004-07-15 2007-08-23 Sayre Chauncey B Reprogramming of adult human testicular stem cells to pluripotent germ-line stem cells
EP1774334B1 (de) 2004-08-03 2017-10-04 Becton, Dickinson and Company Verwendung von magnetischem material zur direkten isolierung von substanzen und fraktionierung von proben, die mehrere komponenten enthalten
ES2313805B1 (es) 2004-10-04 2009-12-23 Cellerix, S.L. Identificacion y aislamiento de celulas multipotentes de tejido mesenquimal no osteocondral.
US8431397B2 (en) 2004-09-14 2013-04-30 The Trustees Of Columbia University In The City Of New York Differentiation of human mesenchymal stem cells to cardiac progenitor cells that promote cardiac repair
US20060234375A1 (en) 2004-09-30 2006-10-19 Doronin Sergey V Use of human stem cells and/or factors they produce to promote adult mammalian cardiac repair through cardiomyocyte cell division
CA2583473A1 (en) 2004-10-05 2007-04-04 University Of Georgia Research Foundation, Inc. Neuronal progenitors from feeder-free human embryonic stem cell culture
FR2877571B1 (fr) 2004-11-05 2007-04-13 Nanobiotix Sarl Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations
WO2006052925A2 (en) 2004-11-08 2006-05-18 The Johns Hopkins University Cardiac stem cells
CA2586276A1 (en) 2004-11-08 2006-05-18 The Johns Hopkins University Bioptome
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US7402151B2 (en) 2004-12-17 2008-07-22 Biocardia, Inc. Steerable guide catheters and methods for their use
EP1674128A1 (de) 2004-12-22 2006-06-28 Steinbeis-Transferzentrum für Herz-Kreislaufforschung Magnetische Polmatrix zur Verwendung für Gewebeherstellung und die Behandlung von Krankheiten
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
WO2006081190A2 (en) 2005-01-25 2006-08-03 Five Prime Therapeutics, Inc. Compositions and methods for treating cardiac conditions
WO2006093276A1 (ja) 2005-03-04 2006-09-08 Kyoto University 心臓組織由来の多能性幹細胞
DE102005016873A1 (de) 2005-04-12 2006-10-19 Magforce Nanotechnologies Ag Nanopartikel-Wirstoff-Konjugate
WO2006108229A1 (en) 2005-04-12 2006-10-19 Angioblast Systems, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
US7846393B2 (en) 2005-04-21 2010-12-07 California Institute Of Technology Membrane filter for capturing circulating tumor cells
GB0508110D0 (en) 2005-04-22 2005-06-01 Univ Keele Gene delivery
WO2006118914A2 (en) 2005-04-29 2006-11-09 Children's Medical Center Corporation Methods of increasing proliferation of adult mammalian cardiomyocytes through p38 map kinase inhibition
US20070003528A1 (en) 2005-06-29 2007-01-04 Paul Consigny Intracoronary device and method of use thereof
US20070014869A1 (en) 2005-07-15 2007-01-18 Cormatrix Cardiovascular, Inc. Compositions for reconstruction, replacement or repair of intracardiac tissue
EP2302034B1 (de) 2005-08-03 2020-10-14 Astellas Institute for Regenerative Medicine Verbesserte Verfahren zur Neuprogrammierung von sommatischen Tierzellen
US20070048383A1 (en) 2005-08-25 2007-03-01 Helmus Michael N Self-assembled endovascular structures
US20070054397A1 (en) 2005-08-26 2007-03-08 Harald Ott Adult cardiac uncommitted progenitor cells
WO2007030834A1 (en) 2005-09-09 2007-03-15 The Trustees Of Columbia University In The City Of New York Chimeric hcn channels
ZA200803929B (en) 2005-10-13 2009-08-26 Anthrogenesis Corp Production of oligodendrocytes from placenta-derived stem cells
US7736346B2 (en) 2005-10-18 2010-06-15 Biocardia, Inc. Bio-interventional therapeutic treatments for cardiovascular diseases
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
CN100355454C (zh) 2005-10-25 2007-12-19 南京工业大学 磁热疗用纳米磁粉－抗人肝癌单抗HAb18靶向药物
EP1945256B1 (de) 2005-10-25 2012-07-04 Women's & Children's Health Research Institute Verfahren und zusammensetzungen zur verbesserung der wundreparatur
CN100509059C (zh) 2005-10-25 2009-07-08 南京工业大学 磁热疗用纳米磁粉-抗cea抗体靶向药物
BRPI0619794B8 (pt) 2005-12-13 2022-06-14 Univ Kyoto Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas
US20090011004A1 (en) * 2005-12-30 2009-01-08 Philadelphia Health & Education Corp., D/B/A/ Drexel University Of College Of Medicine Improved carriers for delivery of nucleic acid agents to cells and tissues
US7875451B2 (en) 2006-01-19 2011-01-25 The University Of Washington Formulation to improve survival of transplanted cells
US7869854B2 (en) 2006-02-23 2011-01-11 Magnetecs, Inc. Apparatus for magnetically deployable catheter with MOSFET sensor and method for mapping and ablation
EP2004237A1 (de) 2006-04-03 2008-12-24 Keele University Gezielte therapie
US20080138416A1 (en) 2006-06-13 2008-06-12 Fmc Biopolymer As Method and systems for using biopolymer-based beads and hydrogels
US8568286B2 (en) 2006-06-14 2013-10-29 Cardiac Pacemakers, Inc. Methods to position therapeutic agents using a magnetic field
US9149564B2 (en) 2006-06-23 2015-10-06 The Regents Of The University Of California Articles comprising large-surface-area bio-compatible materials and methods for making and using them
WO2008008857A2 (en) 2006-07-11 2008-01-17 University Of Utah Research Foundation Thiolated macromolecules and methods of making and using thereof
CA2662795A1 (en) 2006-09-05 2008-03-13 Columbus Nanoworks, Inc. Magnetic particles and methods of making and using the same
JP2010510964A (ja) 2006-09-19 2010-04-08 アシュラジェン インコーポレイテッド 治療的介入の標的としての、ｍｉＲ−１５、ｍｉＲ−２６、ｍｉＲ−３１、ｍｉＲ−１４５、ｍｉＲ−１４７、ｍｉＲ−１８８、ｍｉＲ−２１５、ｍｉＲ−２１６、ｍｉＲ−３３１、ｍｍｕ−ｍｉＲ−２９２−３ｐによって調節される遺伝子および経路
US20080089874A1 (en) 2006-09-28 2008-04-17 The Regents Of The University Of California Directed differentiation and maturation of stem cell-derived cardiomyocytes
EP2489742A1 (de) 2006-10-09 2012-08-22 Julius-Maximilians-Universität Würzburg MicroRNA (MIRNA) zur Diagnose und Therapie von Herzerkrankungen
US8562972B2 (en) 2006-10-23 2013-10-22 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
US7787949B2 (en) 2006-10-30 2010-08-31 Medtronic, Inc. Biological pacemaker compositions and systems incorporating interstitial cells of Cajal
EP2079831A2 (de) 2006-11-07 2009-07-22 Keck Graduate Institute Angereicherte stammzell- und vorläuferzellpopulationen sowie verfahren zur herstellung und verwendung derartiger populationen
KR101240487B1 (ko) 2006-11-09 2013-03-08 더 존스 홉킨스 유니버시티 성체 포유동물 심근세포의 심장 줄기 세포로의 역분화
US8076305B2 (en) 2006-11-30 2011-12-13 Medtronic, Inc. Biological pacemakers including mutated hyperpolarization-activated cyclic nucleotide-gated (HCN) channels
KR100830889B1 (ko) 2006-12-18 2008-05-21 주식회사 케이티 세툭시맵이 결합된 나노 입자 및 이의 제조 방법
DE102007008650B4 (de) 2007-02-20 2012-06-06 Charité - Universitätsmedizin Berlin Zellen zur Therapie des Herzens
DK3399025T3 (da) 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
EP2626416A3 (de) 2007-04-07 2013-12-18 The Whitehead Institute for Biomedical Research Umprogrammierung von somatischen Zellen
US8496926B2 (en) 2007-04-16 2013-07-30 Biocardia, Inc. Treatment for chronic myocardial infarction
US9205112B2 (en) 2007-04-23 2015-12-08 Creative Medical Health, Inc. Combination treatment of cardiovascular disease
US20080297287A1 (en) 2007-05-30 2008-12-04 Magnetecs, Inc. Magnetic linear actuator for deployable catheter tools
FI20075417A0 (fi) 2007-06-05 2007-06-05 Marjo-Riitta Suuronen Koostumuksia ja menetelmiä alkion kantasolujen kasvatukseen
WO2009032456A2 (en) 2007-08-01 2009-03-12 Primegen Biotech Llc Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
US20090136582A1 (en) 2007-08-03 2009-05-28 Albrecht Ralph M Colloidal magnetic nanobioparticles for cytotoxicity and drug delivery
US8292873B2 (en) 2007-08-09 2012-10-23 Boston Scientific Scimed, Inc. Catheter devices for myocardial injections or other uses
US20090081276A1 (en) 2007-08-13 2009-03-26 Eben Alsberg Bioresorbable implant composition
US20090081170A1 (en) 2007-09-13 2009-03-26 Paul Riley Cardiac progenitor cells
EP2203746B1 (de) 2007-09-24 2013-03-06 Technion Research & Development Foundation Ltd. T-zellen-subpopulationen mit fähigkeit zur krebsbehandlung
US8414924B2 (en) 2007-10-10 2013-04-09 Kyoto University Preparation for treating heart disease used in cell therapy
EP2209481B1 (de) 2007-10-15 2013-03-13 Fresenius Medical Care Deutschland GmbH Verwendung von mikrovesikeln (mvs) zur herstellung eines medikaments mit adjuvanter wirkung auf endothelzellen-transplantation, insbesondere bei der behandlung von diabetes durch pankreatische inselzell-transplantation und relevantes verfahren
WO2009058818A2 (en) 2007-10-29 2009-05-07 The Board Of Regents Of The University Of Texas System Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling
DE102007052114B4 (de) 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
US8617877B2 (en) 2007-11-02 2013-12-31 The Johns Hopkins University Cardiac stem cell and myocyte secreted paracrine factors
JP5654352B2 (ja) 2007-11-09 2015-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ｍｉＲ−１５ファミリーのマイクロＲＮＡによる心筋細胞生存及び心臓修復の調節
US8247374B2 (en) 2007-11-09 2012-08-21 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
US8968699B2 (en) 2007-11-15 2015-03-03 The Regents Of The University Of California Switchable nano-vehicle delivery systems, and methods for making and using them
WO2009067644A1 (en) 2007-11-21 2009-05-28 University Of Miami Compositions, systems and methods for obtaining and expanding insulin-producing cells
WO2009070282A1 (en) 2007-11-26 2009-06-04 Stc.Unm Active nanoparticles and method of using
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
AU2008333972A1 (en) 2007-11-30 2009-06-11 New York Medical College Compositions comprising HDAC inhibitors and methods of their use in restoring stem cell function and preventing heart failure
US8124071B2 (en) 2007-11-30 2012-02-28 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
WO2009073616A2 (en) 2007-11-30 2009-06-11 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
CA2743697A1 (en) 2007-11-30 2009-06-11 New York Medical College Methods of isolating non-senescent cardiac stem cells and uses thereof
WO2009079592A2 (en) 2007-12-17 2009-06-25 California Institute Of Technology Modulating immune system development and function through microrna mir-146
US20110110897A1 (en) 2008-01-11 2011-05-12 Schwarz Richard P Adult Human Cardiac-Derived Progenitor Cells
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
US7999025B2 (en) 2008-01-28 2011-08-16 University Of Utah Research Foundation Asymmetrically-functionalized nanoparticles organized on one-dimensional chains
US9078932B2 (en) 2008-02-04 2015-07-14 Emmetrope, Inc. Magnetic cells for localizing delivery and tissue repair
WO2009103818A1 (en) 2008-02-22 2009-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for obtaining progenitor cells and uses thereof in the treatment of tissue or organ damage
CN102014934B (zh) 2008-02-22 2014-08-20 新加坡科技研究局 间充质干细胞颗粒
WO2009120702A2 (en) 2008-03-25 2009-10-01 Emory University Elemental iron nanoparticles
CA2723765A1 (en) 2008-05-08 2009-11-12 Coretherapix Slu Multipotent adult stem cell population
EP2294196A1 (de) 2008-06-06 2011-03-16 Centre National de la Recherche Scientifique - CNRS Verwendung des endolysosomalen systems und sezernierter vesikel (exosomenähnlich) bei behandlungen und diagnostik auf der basis kleiner rna sowie experimentelle untersuchung kleiner rna
AU2009257663B2 (en) 2008-06-09 2014-06-26 New York Medical College Compositions comprising cardiac stem cells overexpressing specific microRNA and methods of their use in repairing damaged myocardium
CN102056591B (zh) 2008-06-11 2013-12-11 刘彦仿 脂质体药剂及其制备方法和用途
WO2009149956A2 (en) 2008-06-13 2009-12-17 Life & Brain Gmbh Fusion protein and use thereof
WO2010033285A2 (en) 2008-06-26 2010-03-25 Spectrum Health Method for treating and preventing radiation damage using genetically modified mesenchymal stem cells
US20130309304A1 (en) 2008-08-05 2013-11-21 Bernardo Nadal-Ginard Compounds and methods
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
US20120034155A1 (en) 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
US8172831B2 (en) 2008-09-02 2012-05-08 Abbott Cardiovascular Systems Inc. Catheter configured for incremental rotation
WO2010059806A2 (en) 2008-11-20 2010-05-27 Cedars-Sinai Medical Center Generation of induced pluripotent stem cells without the use of viral vectors
US20120046242A1 (en) 2008-12-24 2012-02-23 Massachusetts Institute Of Technology Molecular activators of the wnt/beta-catenin pathway
US20110280834A1 (en) 2009-01-16 2011-11-17 Cedars-Sinai Medical Center Methods and compositions for cardiac tissue regeneration
EP2228444A1 (de) 2009-03-09 2010-09-15 Julius-Maximilians-Universität Würzburg microRNA zu Diagnose- und Therapiezwecken bei kardiovaskulären Krankheiten
WO2010118059A1 (en) 2009-04-06 2010-10-14 Capricor, Inc. Systems and methods for cardiac tissue repair
US20120201795A1 (en) 2009-04-29 2012-08-09 Guardian Food Technologies, Llc Inhibition Of Pathogenic Growth On Plant Materials Using Lactic Acid Producing Microorganisms
US9072765B2 (en) 2009-05-20 2015-07-07 Board Of Regents, The University Of Texas System Identification of micro-RNAs involved in post-myocardial infarction remodeling and heart failure
JP5667180B2 (ja) 2009-07-01 2015-02-12 イオン メディックス インコーポレイテッド 哺乳類の有核細胞に由来するマイクロベシクル及びその用途
WO2011020874A1 (en) * 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
US8609617B2 (en) 2009-09-04 2013-12-17 University Of Miami KLF family members regulate intrinsic axon regeneration ability
US9078914B2 (en) 2009-09-10 2015-07-14 Velin-Pharma A/S Method for the preparation of micro-RNA and its therapeutic application
EP2483406A2 (de) 2009-09-30 2012-08-08 President and Fellows of Harvard College Verfahren zur autophagie-modulation durch modulation autophagie-hemmender genprodukte
US20150010640A1 (en) 2009-10-27 2015-01-08 Cedars-Sinai Medical Center Bi-functional compositions for targeting cells to diseased tissues and methods of using same
CN102686264A (zh) 2009-10-27 2012-09-19 雪松-西奈医疗中心 用于具有增强的细胞滞留的靶向细胞递送的外部磁力
US9095629B2 (en) 2009-10-30 2015-08-04 Northwestern University Magnetic nanostructures as theranostic agents
WO2011057251A2 (en) 2009-11-09 2011-05-12 The Brigham And Women's Hospital, Inc. Treatment of heart disease
DK2498796T3 (en) 2009-11-09 2018-03-05 Aal Scient Inc HEART DISEASE TREATMENT
WO2011062244A1 (ja) 2009-11-18 2011-05-26 Kuroda Masahiko キャリア、その製造方法およびその用途
EP2327781A1 (de) 2009-11-27 2011-06-01 RWTH Aachen Mikro-RNA und Gewebereparatur
US20110135577A1 (en) 2009-12-03 2011-06-09 National Taiwan University Superparamagnetic nanoparticles IN MEDICAL THERAPEUTICS and manufacturing method THEREOF
RU2012129900A (ru) 2009-12-15 2014-01-27 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Регуляция микро-рнк при ишемии и ишемически-реперфузионном повреждении
US20130189780A1 (en) 2009-12-31 2013-07-25 Fate Therapeutics, Inc. Reprogramming compositions
EP2371370A1 (de) 2010-04-01 2011-10-05 Johann Wolfgang Goethe-Universität Frankfurt am Main Antagonisten der miRNA-29-Expression und deren Verwendung bei der Prävention und Behandlung von Aortenaneurysmen und Destabilisierung atherosklerotischer Plaques
WO2011127625A1 (zh) 2010-04-13 2011-10-20 江苏命码生物科技有限公司 一种调节生物体内微小核糖核酸含量的方法及其用途
JP5988961B2 (ja) 2010-04-28 2016-09-07 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ 心筋細胞を発生させるための方法
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
EP2385120A1 (de) 2010-05-04 2011-11-09 Justus-Liebig- Universitat Giessen Verwendung von anti-miRNA antisense Oligonucleotiden zur Behandlung von pulmonaler Hypertonie
TWI762890B (zh) 2010-05-12 2022-05-01 開曼群島商英瑞金公司 生物活性腎細胞
AU2011263546B2 (en) 2010-06-10 2015-01-22 Midatech Limited Peptide-carrying nanoparticles
US8980279B2 (en) 2010-07-26 2015-03-17 Qu Biologics Personalized site-specific immunomodulation
WO2012019103A2 (en) 2010-08-06 2012-02-09 The General Hospital Corporation D/B/A System and apparatus for cell treatment
CA2845280A1 (en) 2010-08-13 2012-02-16 Paul Shiels Therapeutic uses of microvesicles and related micrornas
US20120093885A1 (en) 2010-10-18 2012-04-19 Northwestern University Therapeutic vesicles
EP2446929A1 (de) 2010-10-27 2012-05-02 Johann Wolfgang Goethe-Universität Frankfurt am Main Aus atheroprotektiven Endothelzellen abgeleitete Mikrovesikel zur Behandlung und Prävention von atherosklerotischen Leiden
US9248144B2 (en) 2010-11-11 2016-02-02 University Of Miami Compositions, kits and methods for treatment of cardiovascular, immunological and inflammatory diseases
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
CA2829586C (en) 2011-03-11 2021-03-02 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
US8871731B2 (en) 2011-03-16 2014-10-28 Migagen Therapeutics, Inc. Micro-RNA for the regulation of cardiac apoptosis and contractile function
US20140329314A1 (en) 2011-03-29 2014-11-06 Christopher O'Sullivan Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells
US9241950B2 (en) 2011-04-28 2016-01-26 New York University MiR-33 inhibitors and uses thereof to decrease inflammation
WO2012162741A1 (en) 2011-06-01 2012-12-06 Monash University Enrichment of cardiomyocytes
EP2535412A1 (de) 2011-06-17 2012-12-19 Universitat Pompeu-Fabra Neue Behandlung für Muskeldystrophien
EP2549399A1 (de) 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Beurteilung der Wnt-Weg-Aktivität mit probabilistischer Modellierung der Zielgenexpression
US8802144B2 (en) 2011-08-25 2014-08-12 Wisconsin Alumni Research Foundation 3-dimensional cardiac fibroblast derived extracellular matrix
WO2013048734A1 (en) 2011-09-28 2013-04-04 Tufts Medical Center, Inc. Treatment and prevention of cardiovascular disease with cell derived lipid vesicles, microvesicles and exosomes
US20130280205A1 (en) 2012-01-13 2013-10-24 Georgia Regents University Activators of SGK-1 for Use as Cardioprotective Agents
KR101389850B1 (ko) 2012-05-04 2014-04-29 이화여자대학교 산학협력단 심장전구세포의 배양방법 및 그 용도
WO2013170170A2 (en) 2012-05-10 2013-11-14 Board Of Regents Of The University Of Nebraska Compositions and methods for gene therapy
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP2687219A1 (de) 2012-07-18 2014-01-22 Universität Duisburg-Essen Verwendung von Zubereitungen, umfassend Exosome, die aus mesenchymalen Stammzellen (MSC) zur Prävention und Therapie von entzündlichen Zuständen abgeleitet wurden
CA2879322A1 (en) 2012-07-19 2014-01-23 Reneuron Limited Stem cell microparticles
AU2013302799B2 (en) 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
US9492484B2 (en) 2012-09-27 2016-11-15 The Regents Of The University Of California Cardiosphere derived cell population and methods of use
WO2014066545A1 (en) 2012-10-26 2014-05-01 Cedars-Sinai Medical Center Therapeutic cells depleted of specific subpopulations of cells for use in tissue repair of regeneration
WO2014114465A1 (en) 2013-01-24 2014-07-31 Bernardo Nadal-Ginard Modulation of cardiac stem-progenitor cell differentiation, assays and uses thereof
MX376077B (es) 2013-03-13 2025-03-07 Univ Cincinnati Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2.
EP2971010B1 (de) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulierung und abgabe von modifizierten nukleosid-, nukleotid- und nukleinsäurezusammensetzungen
US20140275976A1 (en) 2013-03-15 2014-09-18 Adventist Health System/Sunbelt, Inc. Global Ventricular Cardiac Diastolic Function Evaluation System and Associated Methods
EP3033418B1 (de) 2013-08-14 2019-12-11 Reneuron Limited Stammzellenmikropartikel und mirna
EP3058089B1 (de) 2013-10-18 2018-12-05 Institut National de la Santé et de la Recherche Médicale (INSERM) Von rny abgeleitete kleine rnas als biomarker für erkrankungen im zusammenhang mit atherosklerose
US11377639B2 (en) 2013-11-15 2022-07-05 Wisconsin Alumni Research Foundation Lineage reprogramming to induced cardiac progenitor cells (iCPC) by defined factors
JP2017501694A (ja) 2013-12-04 2017-01-19 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 診断および療法のためのエキソソーム中のゲノムｄｎａ、ｒｎａおよびタンパク質の分析
SI3083997T1 (sl) 2013-12-20 2020-12-31 Universite De Lausanne Diagnostične, prognostične in terapevtske uporabe dolgih nekodirajočih RNA-jev za srčno bolezen in regenerativno zdravilo
EP3102191A1 (de) 2014-02-05 2016-12-14 Stc.Unm Exosomen als therapeutikum für krebs
US20150328263A1 (en) 2014-05-14 2015-11-19 University Of Maryland, Baltimore Cardiac stem cells for cardiac repair
EP3161482B1 (de) 2014-06-27 2020-08-26 XY Evergreen Technology Company Verfahren zur anreicherung von exosomen aus dem zns
DE102014010254B4 (de) 2014-07-11 2023-06-22 Ottobock Se & Co. Kgaa Orthopädietechnische Gelenkeinrichtung
WO2016054569A1 (en) 2014-10-03 2016-04-07 Cedars-Sinai Medical Center Cardiosphere-derived cells (cdcs) as therapeutic agents for pulmonary hypertension
CA2962444C (en) * 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
EP3204117A4 (de) 2014-10-06 2018-05-09 Cedars-Sinai Medical Center Polarisierung von makrophagen zu einem heilungsphänotyp durch zu einem phänotyp durch von kardiosphäre abgeleitete zellen und durch die von solchen zellen sekretierten exosomen
JP6716564B2 (ja) * 2014-12-03 2020-07-01 カプリコール，インコーポレイテッド 安定したエクソソーム製剤の製造方法
US9885042B2 (en) 2015-01-20 2018-02-06 MiRagen Therapeutics, Inc. miR-92 inhibitors and uses thereof
US11083744B2 (en) 2015-03-20 2021-08-10 Mie University Therapeutic agent associated with suppression of proliferation and metastasis of tumor, which comprises exosomes released from cytotoxic T cells and targets cancer stromal/mesenchymal cells
US10131878B2 (en) 2015-04-06 2018-11-20 Wisconsin Alumni Research Foundation Methods for epicardial differentiation of human pluripotent stem cells
KR101818560B1 (ko) 2015-05-18 2018-01-16 가톨릭관동대학교기술지주 주식회사 줄기세포 유래 미세소포체를 포함하는 부정맥 예방 또는 치료용 약제학적 조성물
US10624849B2 (en) 2015-09-28 2020-04-21 Northwestern University Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites
EP3402543B1 (de) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Aus kardiosphäre stammende zellen und durch solche zellen sekretierte exosomen in der behandlung von herzversagen mit konservierter auswurffraktion
WO2017136652A1 (en) 2016-02-04 2017-08-10 Tarveda Therapeutics, Inc. Stapled peptide conjugates and particles
EP3420086A1 (de) 2016-02-26 2019-01-02 Yale University Zusammensetzungen und verfahren zur verwendung von pirnas bei krebsdiagnostika und -therapeutika
WO2017160884A1 (en) 2016-03-14 2017-09-21 Capricor, Inc. Methods of treating ocular inflammation and chemical injuries of the eye with extracellular vesicles
WO2017173034A1 (en) 2016-03-30 2017-10-05 The University Of North Carolina At Chapel Hill Biological agent-exosome compositions and uses thereof
US11859234B2 (en) 2016-05-06 2024-01-02 The Trustees Of Princeton University Method of monitoring RNase L activity
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
EP4699658A2 (de) 2017-04-19 2026-02-25 Cedars-Sinai Medical Center Verfahren und zusammensetzungen zur behandlung von skelettmuskeldystrophie
ES2785682T3 (es) 2017-07-17 2020-10-07 Univ Masarykova Método de diagnóstico de cáncer colorrectal
JP2020529477A (ja) 2017-08-04 2020-10-08 シーダーズ—シナイ メディカル センター がんの治療及び防止のためのカルディオスフィア由来細胞及びその細胞外小胞
WO2019050071A1 (ko) 2017-09-08 2019-03-14 고려대학교 산학협력단 엑소좀 또는 엑소좀 유래 리보핵산을 포함하는 간섬유증 예방 또는 치료용 조성물
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3746137A4 (de) 2018-01-30 2021-11-24 Capricor, Inc. Für die zelltherapie geeignete aktivierungsinduzierte gewebeeffektorzellen und daraus gewonnene abgeleitete extrazelluläre vesikel
US12146137B2 (en) 2018-02-05 2024-11-19 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and Y-RNAS
US12258594B2 (en) 2018-12-05 2025-03-25 The Broad Institute, Inc. Cas proteins with reduced immunogenicity and methods of screening thereof
WO2020131986A1 (en) 2018-12-21 2020-06-25 Pioneer Hi-Bred International, Inc. Multiplex genome targeting
US20220218757A1 (en) 2019-05-08 2022-07-14 Cedars-Sinai Medical Center Therapeutically active cells and exosomes
WO2021178514A1 (en) 2020-03-04 2021-09-10 Cedars-Sinai Medical Center Cardiosphere-derived cells, exosomes derived therefrom, and methods of using same to treat volumetric muscle loss
WO2021188899A1 (en) 2020-03-20 2021-09-23 Cedars-Sinai Medical Center Cardiosphere-derived cell (cdc) therapy for the treatment of viral infections
CN115698286A (zh) 2020-05-19 2023-02-03 西达-赛奈医疗中心 外泌体衍生的piwi-相互作用rna及使用其的方法

Also Published As

Publication number Publication date
JP7336769B2 (ja) 2023-09-01
WO2018195210A1 (en) 2018-10-25
AU2018255346A1 (en) 2019-11-07
AU2018255346B2 (en) 2024-05-02
EP3612191A4 (de) 2020-12-30
CA3059910A1 (en) 2018-10-25
US11759482B2 (en) 2023-09-19
AU2024205194A1 (en) 2024-08-22
JP7724504B2 (ja) 2025-08-18
EP4699658A2 (de) 2026-02-25
EP3612191A1 (de) 2020-02-26
JP2020517601A (ja) 2020-06-18
US20230381243A1 (en) 2023-11-30
JP2023145784A (ja) 2023-10-11
JP2025157552A (ja) 2025-10-15
US20200121727A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
US20230381243A1 (en) Methods and compositions for treating skeletal muscular dystrophy
JP7746319B2 (ja) 筋ジストロフィーの処置における心筋球由来細胞およびこのような細胞によって分泌されたエキソソーム
US20250250576A1 (en) Methods and compositions for treating atherosclerosis
US20240050523A1 (en) Method for inducing resolutive macrophage and uses therof
US20250152711A1 (en) Compositions and methods for modulating the immune system
Wang et al. CTLA-4 nanovesicles disrupt dendritic cell-driven CD8 T cell priming for myocardial infarction therapy
EP4623928A1 (de) Glp-1r-antagonisten zur behandlung von krebs
US20260028632A1 (en) Nucleic acid agents modulating fas isoforms
HK40120941A (en) Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
Balbi The Human Amniotic Fluid Stem Cell Secretome as a powerful tool to unlock endogenous mechanism of cardiac repair and regeneration
Fiore Strategies to improve muscle repair and the outcome of cell mediated therapies in muscular dystrophy
Marchildon The role of CCAAT/Enhancer Binding Protein beta (C/EBPβ) in skeletal muscle satellite cells after injury and in cancer cachexia

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191016

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031713000

Ipc: A61K0035340000

A4 Supplementary search report drawn up and despatched

Effective date: 20201201

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 21/00 20060101ALI20201125BHEP

Ipc: C12N 5/077 20100101ALI20201125BHEP

Ipc: C12N 15/113 20100101ALI20201125BHEP

Ipc: A61K 35/34 20150101AFI20201125BHEP

Ipc: A61K 31/713 20060101ALI20201125BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230315

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20250708

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CEDARS-SINAI MEDICAL CENTER

Owner name: CAPRICOR, INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MARBAN, EDUARDO

Inventor name: AMINZADEH, MARK A.

Inventor name: ROGERS, RUSSELL

Inventor name: MOSELEY, JENNIFER

Inventor name: RODRIGUEZ-BORLADO, LUIS

Inventor name: KANAGAVELU, SARAVANA

Inventor name: SAKODA, CHRISTOPHER STEWART

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CEDARS-SINAI MEDICAL CENTER

Owner name: CAPRICOR, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20251203

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MARBAN, EDUARDO

Inventor name: AMINZADEH, MARK A.

Inventor name: ROGERS, RUSSELL

Inventor name: MOSELEY, JENNIFER

Inventor name: RODRIGUEZ-BORLADO, LUIS

Inventor name: KANAGAVELU, SARAVANA

Inventor name: SAKODA, CHRISTOPHER STEWART

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: F10

Free format text: ST27 STATUS EVENT CODE: U-0-0-F10-F00 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260311

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018089741

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D